Novo Nordisk Secures U.S. Approval for Awiqli, the First Once-Weekly Basal Insulin for Adults with Type 2 Diabetes Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first and…
Novo Nordisk A/S Reports Up to 2.16% HbA1c Reduction with Triple Agonist UBT251 After 24 Weeks in Phase 2 Trial Among Chinese Patients with Type 2 Diabetes The United Laboratories International Holdings Limited and Novo Nordisk A/S have announced encouraging…
FDA Clears Corcept’s Lifyorli™ (relacorilant) in Combination with Nab-Paclitaxel for Platinum-Resistant Ovarian Cancer Treatment Corcept Therapeutics Incorporated has announced a major regulatory milestone with the approval of its novel therapy, Lifyorli™ (relacorilant), by the U.S. Food and Drug Administration. This…
Incyte Reports New Appointments to Its Executive Leadership Team Incyte has announced a series of key leadership appointments within its executive team, signaling a strategic move to strengthen its organizational structure and support long-term growth across research, development, and commercial…
Ono Pharma Files Application in Japan for Ripretinib (DCC-2618) to Treat Advanced Gastrointestinal Stromal Tumors Ono Pharmaceutical, headquartered in Osaka, Japan, under the leadership of President Toichi Takino, has announced the submission of a regulatory application in Japan for the…
Grifols Advances Plans to Launch IPO for Its U.S. Biopharma Division Grifols has taken a significant strategic step toward reshaping its corporate structure and accelerating long-term growth, as its Strategy Committee has proposed—and its Board of Directors has approved—the potential…
Alnylam Drives Innovation in ATTR-CM Care Through Strategic Collaboration with Viz.ai and Ongoing Support for the American Heart Association Alnylam Pharmaceuticals is spearheading a comprehensive, system-wide initiative aimed at transforming the early detection and management of Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM),…
Pfizer and Valneva Report Positive Phase 3 VALOR Results Showing High Efficacy for Lyme Disease Vaccine Candidate Pfizer Inc. and Valneva SE have announced encouraging topline findings from the pivotal Phase 3 VALOR clinical trial evaluating their investigational Lyme disease…
Roche Launches State-of-the-Art Institute of Human Biology Facility to Advance Next-Generation Human Model Systems in Drug Discovery and Development Roche has officially inaugurated a new state-of-the-art research facility to serve as the home of its Institute of Human Biology (IHB),…
ImmunityBio Secures Macau SAR Authorization for ANKTIVA® in BCG-Unresponsive NMIBC with CIS With or Without Papillary Tumors ImmunityBio, today announced that the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region of the People’s Republic of China has granted…
Bristol Myers Squibb Redefines First-Line Treatment Landscape in Classical Hodgkin Lymphoma with Expanded U.S. and EU Approvals for Opdivo® (nivolumab) Bristol Myers Squibb today announced that Opdivo® (nivolumab) has received approval for two new classical Hodgkin Lymphoma (cHL) indications in the U.S.…
Board Reconstitution at Genmab A/S Accompanied by Employee Grants of Restricted Stock Units and Warrants Genmab A/S has announced key governance updates and employee incentive decisions following the conclusion of its Annual General Meeting (AGM) held on March 19, 2026.…